Clinical trial
A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)
NCT03959488 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)
- Lead sponsor
- AstraZeneca
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- July 30, 2019
- Completion date
- January 20, 2023
- Enrollment
- 925 (actual)
- Sites
- 128
Conditions
As the registry lists them; a condition with its own page is linked.